INTRODUCTORY SESSION
- Welcome and Introduction into the topic – Axel Glasmacher (CDDF/University of Bonn, DE)
- Regulatory Aspects – AML & CLL – Beatriz Flores (EMA/MHRA, UK)
WORKSHOP ON MRD IN AML
- Clinical Overview: MRD in AML – Konstanze Döhner (University Hospital of Ulm, DE)
- European LeukemiaNet Guidelines – Arjan Van De Loodsdrecht (VU University Medical Center, NL)
- Methodological Overview: MRD in AML – Chris Hourigan (National Institutes of Health, USA)
- Consortium on MRD in AML and Industry Perspective – Sharon Mc Bain (Johnson & Johnson, USA)
REGULATORY ASPECTS – AML & CLL – Nicole Gormley (FDA, USA)
WORKSHOP PROGRESS ON MRD IN CLL
- Clinical Overview: MRD in CLL – Matthias Ritgen (University Medical Center Schleswig-Holstein, DE)
- Industry Perspective – Davy Chiodin (Acerta/AstraZeneca, USA)
ROUNDTABLE: LESSONS LEARNED AND OPEN QUESTIONS FOR AML & CLL, NEXT STEPS